Randomized Phase 2 Study Comparing Acalabrutinib to Acalabrutinib and Obinutuzumab in the Treatment of Patients With Early-Stage Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Are at High Risk of Disease Progression
Phase of Trial: Phase II
Latest Information Update: 28 Sep 2018
At a glance
- Drugs Acalabrutinib (Primary) ; Obinutuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 10 Sep 2018 Status changed from not yet recruiting to recruiting.
- 13 Aug 2018 Planned initiation date changed from 20 Jul 2018 to 20 Aug 2018.
- 05 Jun 2018 Planned initiation date changed from 20 May 2018 to 20 Jul 2018.